{
    "ticker": "BDTX",
    "name": "Black Diamond Therapeutics, Inc.",
    "description": "Black Diamond Therapeutics, Inc. is a biotechnology company focused on developing transformative medicines for genetically defined diseases. Founded in 2016 and based in Cambridge, Massachusetts, BDTX leverages its proprietary platform, which combines advanced computational techniques and deep biological insights, to discover and develop novel therapies that target specific genetic mutations. The company's lead program is aimed at treating patients with disorders caused by mutations in the brain and nervous system, including rare and prevalent conditions. Black Diamond's innovative approach allows for the design of highly selective medicines that can address significant unmet medical needs while minimizing off-target effects. The company is committed to advancing precision medicine and aims to transform the lives of patients by delivering effective and targeted therapeutic options. BDTX is actively collaborating with academic institutions and industry partners to accelerate its drug discovery and development efforts, with a focus on bringing its promising candidates into clinical trials. The company's mission centers around the belief that every patient deserves a treatment tailored to their unique genetic makeup, and it strives to be at the forefront of developing such precision therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2016",
    "website": "https://www.blackdiamondtherapeutics.com",
    "ceo": "David L. Stover",
    "social_media": {
        "twitter": "https://twitter.com/BDTXInc",
        "linkedin": "https://www.linkedin.com/company/black-diamond-therapeutics"
    },
    "investor_relations": "https://investors.blackdiamondtherapeutics.com",
    "key_executives": [
        {
            "name": "David L. Stover",
            "position": "CEO"
        },
        {
            "name": "Diana G. Bianchi",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "BDTX-001",
                "BDTX-002"
            ]
        }
    ],
    "seo": {
        "meta_title": "Black Diamond Therapeutics, Inc. | Innovating Precision Medicines",
        "meta_description": "Explore Black Diamond Therapeutics, Inc., a biotechnology company pioneering precision medicine for genetically defined diseases. Learn about our innovative therapies and commitment to patient care.",
        "keywords": [
            "Black Diamond Therapeutics",
            "BDTX",
            "Precision Medicine",
            "Biotechnology",
            "Pharmaceuticals",
            "Genetic Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is Black Diamond Therapeutics known for?",
            "answer": "Black Diamond Therapeutics is known for developing precision medicines targeting genetically defined diseases."
        },
        {
            "question": "Who is the CEO of Black Diamond Therapeutics?",
            "answer": "David L. Stover is the CEO of Black Diamond Therapeutics, Inc."
        },
        {
            "question": "Where is Black Diamond Therapeutics headquartered?",
            "answer": "Black Diamond Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are Black Diamond's main products?",
            "answer": "Black Diamond's main products include BDTX-001 and BDTX-002, which target specific genetic mutations."
        },
        {
            "question": "When was Black Diamond Therapeutics founded?",
            "answer": "Black Diamond Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "REGN",
        "VRTX",
        "AMGN",
        "SHPG"
    ],
    "related_stocks": [
        "AAPL",
        "MSFT",
        "GOOGL",
        "AMZN"
    ]
}